Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Payables (2016 - 2025)

Historic Payables for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $14.3 million.

  • Aytu Biopharma's Payables fell 924.19% to $14.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $14.3 million, marking a year-over-year decrease of 924.19%. This contributed to the annual value of $10.6 million for FY2025, which is 1658.67% down from last year.
  • As of Q4 2025, Aytu Biopharma's Payables stood at $14.3 million, which was down 924.19% from $12.3 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Payables registered a high of $25.1 million during Q1 2023, and its lowest value of $9.4 million during Q3 2021.
  • Its 5-year average for Payables is $14.7 million, with a median of $14.7 million in 2022.
  • As far as peak fluctuations go, Aytu Biopharma's Payables skyrocketed by 12530.1% in 2023, and later plummeted by 5192.22% in 2024.
  • Quarter analysis of 5 years shows Aytu Biopharma's Payables stood at $15.6 million in 2021, then rose by 15.41% to $18.0 million in 2022, then crashed by 36.15% to $11.5 million in 2023, then soared by 36.63% to $15.7 million in 2024, then decreased by 9.24% to $14.3 million in 2025.
  • Its Payables stands at $14.3 million for Q4 2025, versus $12.3 million for Q3 2025 and $10.6 million for Q2 2025.